Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have just received a new diagnosis of multiple myeloma (not a previous or returning diagnosis)
- People for whom doctors have determined that a stem cell transplant (using the patient's own stem cells) is an appropriate treatment option
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities) (confirm with trial site)
- People aged 18 years or older and under 75 years old
- Women who are using effective contraception
- People who have signed an informed consent form agreeing to take part
- People who are able to lie flat and still for 30 minutes
- People who are enrolled in a French social security scheme
Who may not be able to join:
- People diagnosed with a precursor or early-stage condition such as MGUS (a mild abnormality in blood proteins), slow-growing "smouldering" myeloma, non-secreting myeloma, or myeloma that has returned after previous treatment
- People who have already started treatment for myeloma
- People whose doctors have determined that intensive treatment followed by a stem cell transplant is not suitable for them
- People who have another active cancer at the same time
- People with a past history of any blood cancer or solid tumour, unless it was a specific low-risk type of skin cancer (basal cell carcinoma) or a very early-stage cervical abnormality (adenocarcinoma in situ)
- People with a history of sarcoidosis (an inflammatory condition affecting organs)
- People with diabetes that is not well controlled
- People currently taking corticosteroid (steroid) medication on a long-term basis
- People currently being treated with medications that stimulate blood cell production (hematopoietic growth factors)
- People currently experiencing sepsis (a serious whole-body infection response)
- People who experience claustrophobia (fear of enclosed spaces)
- People who have not given their consent to participate
- Women who are pregnant or breastfeeding
- Women who could become pregnant and are not using effective contraception
- People who are under legal guardianship or have had their liberty restricted
- People for whom it would not be possible to attend regular follow-up appointments, for geographic, social, or psychological reasons
- People who have previously had an allergic reaction to either of the two imaging substances used in this trial (18F-fluorodeoxyglucose or 18F-fluorocholine)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 03 43 34 81 16
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
number of hypermetabolic foci of myeloma detected by FCH PET versus by FDG PET during the initial extension assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.